Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Regadenoson · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Regadenoson |
| 2 | ACTIVE_COMPARATOR | Adenoscan |
| Name | Type | Description |
|---|---|---|
| Regadenoson | DRUG | 0.4 mg, bolus intravenous injection |
| Adenosine | DRUG | 0.14 mg/kg/min for 6 minutes, intravenous infusion |
Inclusion Criteria: * Referred for a clinically indicated pharmacological stress SPECT myocardial perfusion imaging study Exclusion Criteria: * Any condition precluding the safe administration of Adenoscan for a SPECT myocardial perfusion imaging study * Pregnant or breast-feeding, or (if pre-men...
Regadenoson is a small molecule being developed by Gilead Sciences for use in patients with Coronary Artery Disease undergoing myocardial perfusion imaging (MPI). It is an investigational drug that has completed Phase 3 clinical trials, though it is not yet approved for this use.
Regadenoson is a small molecule that acts as a coronary vasodilator. It is used during myocardial perfusion imaging to assess blood flow in patients with Coronary Artery Disease. The drug works by increasing blood flow in healthy coronary arteries, which helps detect areas of reduced flow.
Regadenoson is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Coronary Artery Disease.
Regadenoson is in Phase 3 clinical development. It has completed two Phase 3 trials, both of which were randomized, double-blind, and active-controlled. The drug is still investigational and has not been approved by regulatory authorities for use in Coronary Artery Disease.
Regadenoson has been studied in two completed Phase 3 trials: NCT00208299 (ADVANCE MPI 1) with 1,231 patients and NCT00208312 (ADVANCE MPI 2) with 787 patients. Both trials compared Regadenoson to Adenoscan in patients undergoing myocardial perfusion imaging for Coronary Artery Disease.
No, Regadenoson is not the same as Adenoscan. In the ADVANCE MPI trials, Regadenoson was compared against Adenoscan as an active control. Both are used in myocardial perfusion imaging, but they are distinct drugs with different chemical structures and properties.